Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates

Vox Sanguinis

Volumn 100, Issue 4, 2011, Pages 351-358

  Modrow, S ^a   Wenzel, J J ^a   Schimanski, S ^a,d   Schwarzbeck, J ^b   Rothe, U ^b   Oldenburg, J ^c   Jilg, W ^a   Eis Hubinger A M ^c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d INSTITUTE OF PATHOLOGY   (Germany)

Author keywords

Hepatitis virus; Human bocavirus; Iatrogenic transmission; Parvovirus B19; Plasma derived coagulation factor products; Recombinant coagulation factor products

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; VIRUS DNA; VON WILLEBRAND FACTOR;

ARTICLE; BOCAVIRUS; GENE SEQUENCE; GENOTYPE; HEPATITIS A VIRUS; HEPATITIS E VIRUS; HUMAN PARVOVIRUS 4; HUMAN PARVOVIRUS B19; NONHUMAN; PARECHOVIRUS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SAFETY; VIRUS DETECTION; VIRUS TRANSMISSION;

BLOOD COMPONENT TRANSFUSION; DNA, VIRAL; HEPATITIS A; HEPATITIS A VIRUS, HUMAN; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS; POLYMERASE CHAIN REACTION; RNA, VIRAL;

EID: 79954552034     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2010.01445.x     Document Type: Article

References (58)

1. Laub R, Strengers P: Parvoviruses and blood products. Pathol Biol (Paris) 2002; 50:339-348
2. Robertson BH, Erdman DD: Non-enveloped viruses transmitted by blood and blood products. Dev Biol (Basel) 2000; 102:29-35
3. Parsyan A, Candotti D: Human erythrovirus B19 and blood transfusion - an update. Transfus Med 2007; 17:263-278
4. Webert KE, Cserti CM, Hannon J, et al.: Proceedings of a Consensus conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev 2008; 22:1-34
5. Chudy M, Budek I, Keller-Stanislawski B, et al.: A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J Med Virol 1999; 57:91-99
6. Baylis SA, Fryer JF, Grabarczyk P: Effects of probe binding mutations in an assay designed to detect parvovirus B19: implications for the quantitation of different virus genotypes. J Virol Meth 2007; 139:97-99
7. Allain JP, Thomas I, Sauleda S: Nucleic acid testing for emerging viral infections. Transfus Med 2002; 12:275-283
8. Young NS, Brown KE: Parvovirus B19. N Engl J Med 2004; 350:586-597
9. de Jong EP, de Haan TR, Kroes AC, et al.: Parvovirus B19 infection in pregnancy. J Clin Virol 2006; 36:1-7
10. Lindner J, Karalar L, Schimanski S, et al.: Clinical and epidemiological aspects of human bocavirus infection. J Clin Virol 2008; 43:391-395
11. Karalar L, Lindner J, Schimanski S, et al.: Prevalence and clinical aspects of human bocavirus infection in children. Clin Microbiol Infect 2010; 16:633-639
12. Jones MS, Kapoor A, Lukashov VV, et al.: New DNA viruses identified in patients with acute viral infection syndrome. J Virol 2005; 79:8230-8236
13. Simmonds P, Manning A, Kenneil R, et al.: Parenteral transmission of the novel human parvovirus PARV4. Emerg Infect Dis 2007; 13:1386-1388
14. Schneider B, Fryer JF, Reber U, et al.: Persistence of novel human parvovirus PARV4 in liver tissue of adults. J Med Virol 2008; 80:345-351
15. Sharp CP, Lail A, Donfield S, et al.: High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. J Infect Dis 2009; 200:1119-1125
16. Brown KE, Simmonds P: Parvoviruses and blood transfusion. Transfusion 2007; 47:1745-1750
17. Soucie JM, Robertson BH, Bell BP, et al.: Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion 1998; 38:573-579
18. Gerritzen A, Schneweis KE, Brackmann HH, et al.: Acute hepatitis A in haemophiliacs. Lancet 1992; 340:1231-1232
19. Gowland P, Fontana S, Niederhauser C, et al.: Molecular and serologic tracing of a transfusion-transmitted hepatitis A virus. Transfusion 2004; 44:1555-1561
20. Arankalle VA, Chobe LP: Hepatitis E virus: can it be transmitted parenterally? J Viral Hepat 1999; 6:161-164
21. Matsubayashi K, Nagaoka Y, Sakata H, et al.: Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan. Transfusion 2004; 44:934-940
22. Matsubayashi K, Kang JH, Sakata H, et al.: A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route. Transfusion 2008; 48:1368-1375
23. Boxall E, Herborn A, Kochethu G, et al.: Transfusion-transmitted hepatitis E in a 'nonhyperendemic' country. Transfus Med 2006; 16:79-83
24. Colson P, Coze C, Gallain P, et al.: Transfusion-associated hepatitis E, France. Emerg Infect Dis 2007; 13:648-649
25. Groeneveld K, van der Noordaa J: Blood products and parvovirus B19. Neth J Med 2003; 61:154-156
26. Schmidt I, Blümel J, Seitz H, et al.: Parvovirus B19 DNA in plasma pools and plasma derivatives. Vox Sang 2001; 81:228-235
27. Lefrère JJ, Servant-Delmas A, Candotti D, et al.: Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood 2005; 106:2890-2895
28. Siegl G, Cassinotti P: Presence and significance of parvovirus B19 in blood and blood products. Biologicals 1998; 26:89-94
29. Fryer JF, Hubbard AR, Baylis SA: Human parvovirus PARV4 in clotting factor VIII concentrates. Vox Sang 2007; 93:341-347
30. Food and Drug Administration, U.S. Department of Health and Human Services: Guidance for Industry. Nucleic acid testing to reduce the possible risk of human parvovirus B19 transmission by plasma-derived products.
31. Council of Europe: Human plasma (pooled and treated for virus inactivation), Monograph 1646, 6th edn. Strassbourg, France, European Pharmacopoeia, 2008
32. European Medicines Agency, Committee for Medical Products in Human Use: Guideline on plasma-derived medicinal products, CPMP/BWP/269/95 rev 4, 2009
33. Schneider B, Fryer JF, Oldenburg J, et al.: Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4. Haemophilia 2008; 14:978-986
34. Liefeldt L, Plentz A, Klempa B, et al.: Recurrent high level parvovirus B19/genotype 2 viremia in a renal transplant recipient analyzed by real-time PCR for simultaneous detection of genotypes 1 to 3. J Med Virol 2005; 75:161-169
35. Lindner J, Karalar L, Zehentmeier S, et al.: Humoral immune response against human bocavirus VP2 virus-like particles. Viral Immunol 2008; 21:443-449
36. Fryer JF, Delwart E, Hecht FM, et al.: Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals. Transfusion 2007; 47:1054-1061
37. Houde A, Guévremont E, Poitras E, et al.: Comparative evaluation of new TaqMan real-time assays for the detection of hepatitis A virus. J Virol Methods 2007; 140:80-89
38. Brost S, Wenzel JJ, Ganten TM, et al.: Sporadic cases of acute autochthonous hepatitis E virus infection in Southwest Germany. J Clin Virol 2010; 47:89-92
39. Stamoulis K, Sofroniadou K: Virus inactivation of plasma and its derivatives. Haema 2002; 5:213-221
40. Schmidt M, Themann A, Drexler C, et al.: Blood donor screening for parvovirus B19 in Germany and Austria. Transfusion 2007; 47:1775-1782
41. Rinckel LA, Buno BR, Gierman TM, et al.: Discovery and analysis of a novel parvovirus B19 Genotype 3 isolate in the United States. Transfusion 2009; 49:1488-1492
42. Hübschen JM, Mihneva Z, Mentis AF, et al.: Phylogenetic analysis of human parvovirus B19 sequences from eleven different countries confirms the predominance of genotype 1 and suggests the spread of genotype 3b. J Clin Microbiol 2009; 47:3735-3738
43. Corcoran C, Hardie D, Yeats J, et al.: Genetic variants of human parvovirus B19 in South Africa: cocirculation of three genotypes and identification of a novel subtype of genotype 1. J Clin Microbiol 2010; 48:137-142
44. Geng Y, Wu C-G, Bhattacharyya SP, et al.: Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing. Transfusion 2007; 47:883-889
45. Plentz A, Hahn J, Knöll A, et al.: Exposure of hematologic patients to parvovirus B19 as a contaminant of blood cell preparations and blood products. Transfusion 2005; 45:1811-1815
46. Wu CG, Mason B, Jong J, et al.: Parvovirus B19 transmission by a high-purity factor VIII concentrate. Transfusion 2005; 45:1003-1010
47. Kleinman SH, Glynn SA, Lee TH, et al.: National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study-II (NHLBI REDS-II). A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood 2009; 114:3677-3683
48. Röhrer C, Gärtner B, Sauerbrei A, et al.: Seroprevalence of parvovirus B19 in the German population. Epidemiol Infect 2008; 136:1564-1575
49. Blümel J, Schmidt I, Effenberger W, et al.: Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 2002; 42:1473-1481
50. Lindblom A, Heyman M, Gustafsson I, et al.: Parvovirus B19 infection in children with acute lymphoblastic leukemia is associated with cytopenia resulting in prolonged interruptions of chemotherapy. Clin Infect Dis 2008; 46:528-536
51. Eis-Hübinger AM, Drexler JF, Reber U, et al.: Absence of detection of novel human parvoviruses in German plasma donations. Transfusion 2010; 50:266-267
52. Touinssi M, Brisbarre N, Picard C, et al.: Parvovirus 4 in blood donors, France. Emerg Infect Dis 2010; 16:165-166
53. Servant-Delmas A, Laperche S, Mercier M, et al.: Human parvovirus 4 in recipients of cellular products and in blood donors: epidemiologic similarity with B19 parvovirus. Transfusion 2009; 49:1771-1773
54. Eis-Hübinger AM, Sasowski U, Brackmann HH, et al.: Parvovirus B19 DNA is frequently present in recombinant coagulation factor VIII products. Thromb Haemost 1996; 76:1120
55. Key NS, Negrier C: Coagulation factor concentrates: past, present, and future. Lancet 2007; 370:439-448
56. Meeks SL, Josephson CD: Should hemophilia treaters switch to albumin-free recombinant factor VIII concentrates. Curr Opin Hematol 2006; 13:457-461
57. Farrugia A: Guide for the Assessment of Clotting Factor Concentrates. The World Health Federation of Hemophilia 2008
58. Jitschin R, Peters O, Plentz A, et al.: Impact of Parvovirus B19 Infection on Pediatric Patients with Hematologic and/or Oncologic Disorders. Clin Microbiol Infect 2010; DOI: 10.1111/j.1469-0691.2010.03355.x